All

Results: 35209-35220 of 41262

PR Newswire associated0

Trip.com sees increase in visits after China expands visa-free travel to 6 countries

PR Newswire associated0

FP Markets Expands its Commodity CFDs Offering adding Lead, Nickel, Aluminium, Zinc and Copper and Spot Silver & Gold vs a range of cross currencies

PR Newswire associated0

Fitness Superstore announce partnership with professional athlete Zack George

Transat Jacques Vabre: Alberto Bona and Pablo Santurde del Arco on the Class40 IBSA after crossing the finish line in Fort-de-France, Martinique (©IBSA | Beppe Raso)

Alberto Bona on Board the Class40 IBSA Finishes the Transat Jacques Vabre in Third Place

Aker Carbon Capture awarded FEED for Hafslund Oslo Celsio's CCS project on their waste-to-energy plant at Klemetsrud in Norway

STEMCELL Technologies, Canada’s largest biotechnology company, has received the Canada's Most Admired Corporate Cultures™ of 2023 award by Waterstone Human Capital. This national awards program recognizes best-in-class Canadian organizations for fostering high-performance corporate cultures that help sustain a competitive advantage. (Graphic: Business Wire)

STEMCELL Technologies Wins a Canada’s Most Admired Corporate Cultures™ of 2023 Award

FPT Software and RWE’s 10-year partnership anniversary ceremony was hosted in Hanoi, Vietnam with presence of both sides’ senior executives. (Photo: Business Wire)

FPT Software and RWE Strengthen European Strategic Partnership

PA Media Press Centres associated0

Westgate Oxford Launches ‘WasteLess Wonderland’ a Pioneering New Christmas Experience for 2023, Designed and Curated by HemingwayDesign

AI-enabled Home Healthcare Provider Cera Care to Save the UK Government & Hospitals £100M This Winter by Committing to 5 Million Care Visits

Mara Renewables Appoints Harry Boot, Long-Time Food Ingredient Executive as CEO

Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO® in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations

DxVx, plans to make a license-in agreement of OVM-200 and conduct clinical trials in Asia